HR 1266

Summary

Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA). Xylazine, also known as tranq , is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine. This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused. Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA. The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs. The bill also exempts xylazine manufacturers from the CSA's physical security requirements. Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.

Bill status

Status

Passed House

Sponsor

Rep. Jimmy Panetta [D-CA-19]

Cosponsors

114

Policy area

Crime and Law Enforcement

Introduced

2025-02-12

Latest action

2026-09-16: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.

Committee referrals

• Judiciary Committee: House · Discharged From · 2026-09-14
• Energy and Commerce Committee: House · Reported By · 2026-09-14
• Energy and Commerce Committee: House · Markup By · 2026-07-21
• Energy and Commerce Committee: House · Markup By · 2026-07-20
• Judiciary Committee: House · Referred To · 2025-02-12

Recent actions

• 2026-09-16: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
• 2026-09-15: Motion to reconsider laid on the table Agreed to without objection.
• 2026-09-15: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672)
• 2026-09-15: Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
• 2026-09-15: DEBATE - The House proceeded with forty minutes of debate on H.R. 1266.